Thursday, 25 Apr 2019

You are here

Recurrent Uveitis Increases the Risk of Ankylosing Spondylitis

Arthritis Research and Therapy reports on the epidemiologic association between recurrent anterior uveitis and ankylosing spondylitis (AS) noting that as the number of uveitis episodes increases, so does the incidence of AS.

Uveitis is the most common extra-articular manifestation of AS, occurring in up to 40% of AS patients. As such AS-related anterior uveitis may first present to the ophthalmologist, not by a rheumatologist.  These investigators asked the question - how oftent does recurrent anterior uveitis result in subsequent AS. 

A national cohort of10,483 patients with new-onset uveitis (seen between 2004 -2013) was compared to 52415 matched control subjects (never had uveitis).

After the first uveitis episode, the AS risk was 7 fold higher (incidence rate ratio = 7.4 compared to normal controls).

After the the second uveitis episode, the IRR further increased to 17.71.  High rates of AS were seen in both male and female patients with recurrent uveitis (IRR 284.1 and 268.7 per 100,000 person-years, respectively.

As disease controls, patients with RA or herniatiated vertebral discs did not show a correlation with the occurrence or recurrence of uveitis.

The risk of subsequent AS increased with the number of episodes of anterior uveitis. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Skyrizi (risankizumab) FDA Approved for Psoriasis

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Skyrizi is an interleukin-23 (IL-23) inhibitor that was also recently approved in Canada and Japan. Skyrizi is the third IL-23 inhibitor (behind guselkumab [Tremfya] and tildrakizumab [Ilumya]) to be approved in the last year.

Higher Comorbidities in Hidradenitis Suppurativa

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

A cross-sectional study compared 5306 HS patients, 14 037 patients with psoriasis, and 1 733 810 controls from electronic health records between 2013 and 2018. Specifically they examined comorbidities using the Charlson Comorbidity Index (CCI) score.

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed. 

AAD/NPF Guidelines on Biologic Use in Psoriasis

Menter and colleagues from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) have published their expert consensus guidelines for the use of biologics in psoriasis.